Issue Cover

Industry Insights

A deeper dive into the pharmaceutical industry

Articles

article-item
Unmet needs in primary biliary cholangitis: Understanding challenges

How is primary biliary cholangitis (PBC) currently affecting patients; and, more importantly, what hopes does PBC Awareness Month bring for new treatment options?

5 September 2024Europe
article-item
Precision medicine and the role of pathologists in multidisciplinary bladder cancer care

How can the combined power of multidisciplinary teams and precision medicine be harnessed for people living with bladder cancer?

5 September 2024Industry Insights
article-item
How the surging interest in oral peptides is opening new horizons in GLP-1

Oral peptides are becoming an attractive drug candidate due to their efficacy and potency. How are parenteral drug products impacting the distribution of this new candidate?

5 September 2024Industry Insights
article-item
Sustainable drug delivery devices: striking a balance between aspirations and current possibilities

Alex Fong and Olivia Houselander from Owen Mumford Pharmaceutical Services consider the action needed to make drug discovery processes more sustainable

17 July 2024Industry Insights
article-item
Exploring disease modification to change the future of epilepsy treatment

Konrad Werhahn from UCB discusses how disease-modifying solutions may introduce a new era in treatment for epilepsies

17 July 2024Industry Insights
article-item
20 years of EGFR in NSCLC: how precision medicine helps navigate lung cancer challenges

Henar Hevia at Johnson & Johnson considers the progress that has been made in lung cancer treatment since the discovery of EGFR, including the evolving treatment paradigm, the role of precision medicine in treatment decision-making and quality of life for patients receiving targeted treatments

4 June 2024Industry Insights
article-item
Paediatric clinical trials for obesity treatment

Alan Baldridge and Heather Peterson from ICON consider the prevalence of paediatric obesity and assess clinical trials of its treatments

4 June 2024Industry Insights
article-item
Epilepsy and brain health: a call for global action and unity

Rafal Kaminski from Angelini Pharma tells Pharmafocus about the global challenge of epilepsy as well as how his company is striving to bridge the gaps in epilepsy treatment

28 April 2024Industry Insights
article-item
Rare disease clinical trials: the urgent need for patients to be heard

Ahead of clinical trials day, Soraya Bekkali, from Alexion, AstraZeneca Rare Disease, highlights the urgent need to elevate patients’ voices to accelerate rare disease innovation

28 April 2024Industry Insights
article-item
Psychedelic medicines and the treatment of neurological conditions

Rob Conley from Beckley Psytech tells Pharmafocus about the use of psychedelic medicine for the treatment of psychiatric and neurological conditions, and how this field could develop in the future

28 April 2024Industry Insights
article-item
Psychoactives in mental health treatment

Kabir Nath from Compass Pathways explores the need for new treatments in the mental health space, as well as assessing whether psychoactives could be the way forward

28 April 2024Industry Insights
article-item
Compliant connections: making instant messaging work for biopharma field teams

Sebastien Noel from Veeva Systems considers the potential benefits and drawbacks of messaging services for HCPs as well as explaining Veeva’s own platform, which combats these issues

7 April 2024Industry Insights